Evaluation of siddha trial drug kana mantha mathirai for kana mantham (Gastro Enteritis)

Phase II Non Randomized Clinical Study On Kana Mantham (Gastro Enteritis)with the Evaluation of Siddha trial drug Kana Mantha Mathirai in Children

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/10/037531

Enrollment

Registered

2021-10-25

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K929- Disease of digestive system, unspecified

Interventions

Intervention1: Kana mantha mathirai: 0.7 mg of tablet bd for 21 days Control Intervention1: nil : nil

Eligibility

Inclusion criteria

Inclusion criteria: Diarrhea fever Bloating abdomen Headache watery nasal discharge weight loss

Exclusion criteria

Exclusion criteria: Protein energy malnutrition severe dehydration Tuberculosis Pneumonia

Design outcomes

Primary

Measure	Time frame
Reduction in Vesikari score Reduction in clinical symptoms Timepoint: 14 days	—

Secondary

Measure	Time frame
Comparing safety parameters before and after treatmentTimepoint: 14 days	—

Countries

India

Contacts

Public ContactDr v Gayathri

Governnment siddha medical college

drvranimd@yahoo.com6369113461

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026